Up-regulation of Biglycan is Associated with Poor Prognosis and PTEN Deletion in Patients with Prostate Cancer

Biglycan (BGN), a proteoglycan of the extracellular matrix, is included in mRNA signatures for prostate cancer aggressiveness. To understand the impact of BGN on prognosis and its relationship to molecularly defined subsets, we analyzed BGN expression by immunohistochemistry on a tissue microarray containing 12,427 prostate cancers. Seventy-eight percent of 11,050 interpretable cancers showed BGN expression, which was considered as low intensity in 47.7% and as high intensity in 31.1% of cancers. BGN protein expression rose with increasing pathological tumor stage, Gleason grade, lymph node metastasis and early PSA recurrence (P < .0001 each). Comparison with our molecular database attached to the TMA revealed that BGN expression was linked to presence of TMPRRS2:ERG fusion and PTEN deletion (P < .0001 each). In addition, BGN was strongly linked to androgen-receptor (AR) levels (P < .0001), suggesting a hormone-depending regulation of BGN. BGN up-regulation is a frequent feature of prostate cancer that parallels tumor progression and may be useful to estimate tumor aggressiveness particularly if combined with other molecular markers.

[1]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[2]  G. Ayala,et al.  Reactive stroma in human prostate cancer: induction of myofibroblast phenotype and extracellular matrix remodeling. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[3]  E. Chien,et al.  Androgen-regulated cervical ripening: a structural, biomechanical, and molecular analysis. , 2008, American journal of obstetrics and gynecology.

[4]  A. Piga,et al.  Biglycan expression and clinical outcome in patients with pancreatic adenocarcinoma , 2013, Tumor Biology.

[5]  W. Zimmer,et al.  Synergistic immunologic targets for the treatment of prostate cancer , 2016, Experimental biology and medicine.

[6]  Jin Woo Kim,et al.  DNA copy number alterations in prostate cancers: A combined analysis of published CGH studies , 2007, The Prostate.

[7]  Ian G. Mills,et al.  The role of glycans in the development and progression of prostate cancer , 2016, Nature Reviews Urology.

[8]  G. Petrovski,et al.  The cytoprotective effect of biglycan core protein involves Toll-like receptor 4 signaling in cardiomyocytes. , 2016, Journal of molecular and cellular cardiology.

[9]  H. Xu,et al.  Androgen receptor: structure, role in prostate cancer and drug discovery , 2014, Acta Pharmacologica Sinica.

[10]  Xiaohu Gu,et al.  Biglycan up-regulated vascular endothelial growth factor (VEGF) expression and promoted angiogenesis in colon cancer , 2015, Tumor Biology.

[11]  M. Kahn,et al.  The Wnt signaling pathway in cancer. , 2016, Critical reviews in oncology/hematology.

[12]  R. Iozzo,et al.  Biological interplay between proteoglycans and their innate immune receptors in inflammation , 2013, The FEBS journal.

[13]  Rikang Wang,et al.  TGF-β stimulates biglycan core protein synthesis but not glycosaminoglycan chain elongation via Akt phosphorylation in vascular smooth muscle , 2011, Growth factors.

[14]  M. Kurosaka,et al.  PTEN regulates matrix synthesis in adult human chondrocytes under oxidative stress , 2014, Journal of orthopaedic research : official publication of the Orthopaedic Research Society.

[15]  Marian F Young,et al.  The matrix component biglycan is proinflammatory and signals through Toll-like receptors 4 and 2 in macrophages. , 2005, The Journal of clinical investigation.

[16]  J. Kononen,et al.  Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.

[17]  C. Eng,et al.  GATA2 negatively regulates PTEN by preventing nuclear translocation of androgen receptor and by androgen-independent suppression of PTEN transcription in breast cancer. , 2012, Human molecular genetics.

[18]  B. Seliger,et al.  HER-2/neu-mediated Down-regulation of Biglycan Associated with Altered Growth Properties* , 2012, The Journal of Biological Chemistry.

[19]  T. Zeng,et al.  High expression of biglycan is associated with poor prognosis in patients with esophageal squamous cell carcinoma. , 2013, International journal of clinical and experimental pathology.

[20]  J. Korbel,et al.  Genomic deletion of MAP3K7 at 6q12-22 is associated with early PSA recurrence in prostate cancer and absence of TMPRSS2:ERG fusions , 2013, Modern Pathology.

[21]  Roger R. Gomis,et al.  TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4 , 2008, Cell.

[22]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[23]  C. Plass,et al.  Genomic deletion of PTEN is associated with tumor progression and early PSA recurrence in ERG fusion-positive and fusion-negative prostate cancer. , 2012, The American journal of pathology.

[24]  D. Watson,et al.  Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies , 2013, BMC Genomics.

[25]  Tim Beißbarth,et al.  TMPRSS2-ERG -specific transcriptional modulation is associated with prostate cancer biomarkers and TGF-β signaling , 2011, BMC Cancer.

[26]  J. Fischer,et al.  Transcriptional and posttranscriptional regulators of biglycan in cardiac fibroblasts , 2009, Basic Research in Cardiology.

[27]  J. Fischer,et al.  Inhibitory Role of the Small Leucine-Rich Proteoglycan Biglycan in Bladder Cancer , 2013, PloS one.

[28]  Yiqing Zhao,et al.  Regulation of paxillin-p130-PI3K-AKT signaling axis by Src and PTPRT impacts colon tumorigenesis , 2016, Oncotarget.

[29]  Ning Yang,et al.  Expression and significance of biglycan in endometrial cancer , 2014, Archives of Gynecology and Obstetrics.

[30]  Hua-mei Tang,et al.  Biglycan expression correlates with aggressiveness and poor prognosis of gastric cancer , 2011, Experimental biology and medicine.

[31]  H. Schlüter,et al.  ERG Status Is Unrelated to PSA Recurrence in Radically Operated Prostate Cancer in the Absence of Antihormonal Therapy , 2011, Clinical Cancer Research.

[32]  J. Fischer,et al.  Interindividual Transcriptional Regulation of the Human biglycan Gene Involves Three Common Molecular Haplotypes , 2013, Arteriosclerosis, thrombosis, and vascular biology.

[33]  Bingya Liu,et al.  Biglycan enhances gastric cancer invasion by activating FAK signaling pathway , 2014, Oncotarget.

[34]  N. D. de Araújo,et al.  Expression of extracellular matrix proteins in adenomatoid odontogenic tumor. , 2010, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[35]  Ronald Simon,et al.  Recipient block TMA technique. , 2010, Methods in molecular biology.

[36]  K. Rungsrisuriyachai,et al.  Ets Related Gene and Smad3 Proteins Collaborate to Activate Transforming Growth Factor-Beta Mediated Signaling Pathway in ETS Related Gene-Positive Prostate Cancer Cells. , 2014, Journal of pharmaceutical sciences and pharmacology.

[37]  V. Beneš,et al.  Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. , 2013, Cancer cell.

[38]  S. Iacob,et al.  Biglycan regulates the expression of EGF receptors through EGF signaling pathways in human articular chondrocytes , 2010, Connective tissue research.

[39]  C. Sander,et al.  Integrative genomic profiling of human prostate cancer. , 2010, Cancer cell.

[40]  Eleni Bazigou,et al.  Cell signaling and cancer , 2007, Genome Biology.

[41]  Li-li Zhang,et al.  Biglycan enhances the ability of migration and invasion in endometrial cancer , 2016, Archives of Gynecology and Obstetrics.

[42]  E. Reddy,et al.  Molecular Mechanism of Activation of Transforming Growth Factor Beta/Smads Signaling Pathway in Ets Related Gene-Positive Prostate Cancers. , 2014, Journal of pharmaceutical sciences and pharmacology.

[43]  H. Huland,et al.  Numerical chromosomal aberrations in transition-zone carcinomas of the prostate. , 1997, The Journal of urology.

[44]  A J Bailey,et al.  Changes in collagen metabolism in prostate cancer: a host response that may alter progression. , 2001, The Journal of urology.

[45]  T. Gress,et al.  Biglycan is overexpressed in pancreatic cancer and induces G1-arrest in pancreatic cancer cell lines. , 2001, Gastroenterology.

[46]  L. Hood,et al.  Quantitative proteomics analysis integrated with microarray data reveals that extracellular matrix proteins, catenins, and p53 binding protein 1 are important for chemotherapy response in ovarian cancers. , 2009, Omics : a journal of integrative biology.

[47]  G. Sauter,et al.  CHD1 is a 5q21 tumor suppressor required for ERG rearrangement in prostate cancer. , 2013, Cancer research.

[48]  M. Brawer,et al.  Comparison of microscopic vascularity in benign and malignant prostate tissue. , 1993, Human pathology.

[49]  Marian F Young,et al.  Biglycan , 2012, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[50]  J. Tchinda,et al.  Recurrent fusion of TMPRSS2 and ETS transcription factor genes in prostate cancer. , 2006, Science.

[51]  M. Young,et al.  Transforming growth factor beta stimulation of biglycan gene expression is potentially mediated by sp1 binding factors , 2004, Journal of cellular biochemistry.

[52]  S. Kurtz,et al.  Recurrent deletion of 3p13 targets multiple tumour suppressor genes and defines a distinct subgroup of aggressive ERG fusion‐positive prostate cancers , 2013, The Journal of pathology.

[53]  Yuehua Gong,et al.  Up-regulated biglycan expression correlates with the malignancy in human colorectal cancers , 2012, Clinical and Experimental Medicine.

[54]  Bruce J Trock,et al.  Upgrading and downgrading of prostate cancer from biopsy to radical prostatectomy: incidence and predictive factors using the modified Gleason grading system and factoring in tertiary grades. , 2012, European urology.

[55]  Junqing Ma,et al.  Biglycan mediates suture expansion osteogenesis via potentiation of Wnt/β-catenin signaling. , 2015, Journal of biomechanics.

[56]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[57]  Yuxin Yin,et al.  The tumor suppressor PTEN has a critical role in antiviral innate immunity , 2015, Nature Immunology.

[58]  R. Iozzo,et al.  Biological Functions of the Small Leucine-rich Proteoglycans: From Genetics to Signal Transduction* , 2008, Journal of Biological Chemistry.

[59]  P. Little,et al.  Androgens stimulate human vascular smooth muscle cell proteoglycan biosynthesis and increase lipoprotein binding. , 2005, Endocrinology.

[60]  A. Haese*,et al.  Clinical Utility of Quantitative Gleason Grading in Prostate Biopsies and Prostatectomy Specimens. , 2016, European urology.

[61]  E. Ruoslahti,et al.  Interaction of the small interstitial proteoglycans biglycan, decorin and fibromodulin with transforming growth factor beta. , 1994, The Biochemical journal.

[62]  Y. Ohba,et al.  Tumour endothelial cells in high metastatic tumours promote metastasis via epigenetic dysregulation of biglycan , 2016, Scientific Reports.

[63]  H. He,et al.  SOX9 drives WNT pathway activation in prostate cancer. , 2016, The Journal of clinical investigation.